Cryo-Cell International, Inc. (CCEL) is a Medical - Care Facilities company in the Healthcare sector, currently trading at $3.67. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CCEL = $10.44 (+184.5% from the current price, the stock appears undervalued). Analyst consensus target is CCEL = $9 (+131.6% upside).
Valuation: CCEL trades at a trailing Price-to-Earnings (P/E) of -12.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.98.
Financials: revenue is $32M, +1.4%/yr average growth. Net income is $2M (loss), growing at -347.8%/yr. Net profit margin is -7.7% (negative). Gross margin is 76.6% (+5.6 pp trend).
Balance sheet: total debt is $3M with negative equity of -$19M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.59 (tight liquidity). Debt-to-assets is 5.2%. Total assets: $62M.
Analyst outlook: 0 / 1 analysts rate CCEL as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 30/100 (Fail), Past 50/100 (Partial), Health 0/100 (Fail), Moat 50/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
